ARCA BIOPHARMA ANNOUNCES PHASE 2B GENETIC-AF ATRIAL FIBRILLATION BURDEN (AFB) RESULTS SELECTED FOR PRESENTATION AT AMERICAN HEART ASSOCIATION 2018 SCIENTIFIC SESSIONS